Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour

J Med Vasc. 2020 Apr;45(2):90-92. doi: 10.1016/j.jdmv.2020.01.152. Epub 2020 Feb 6.

Authors

P Kubicek¹, E Boughalem¹, C Frere²; Groupe Francophone Thrombose et Cancer

Affiliations

¹ Institut de cancérologie de l'Ouest, Site Paul-Papin, Angers, France.
² Inserm UMRS_1166, Institute of Cardiometabolism and Nutrition, GRC 27 GRECO, Sorbonne Université, 75013 Paris, France; Biological hematology department, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France; Groupe francophone thrombose et cancer, 75010 Paris, France. Electronic address: corinne.frere@aphp.fr.

PMID: 32265022
DOI: 10.1016/j.jdmv.2020.01.152

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anticoagulants / adverse effects*
Antineoplastic Agents / therapeutic use*
Aspirin / adverse effects*
Cisplatin / therapeutic use*
Enoxaparin / adverse effects*
Hemorrhage / chemically induced*
Humans
Male
Mediastinal Neoplasms / complications
Mediastinal Neoplasms / diagnostic imaging
Mediastinal Neoplasms / drug therapy*
Middle Aged
Neoplasms, Germ Cell and Embryonal / complications
Neoplasms, Germ Cell and Embryonal / diagnostic imaging
Neoplasms, Germ Cell and Embryonal / drug therapy*
Primary Prevention*
Risk Assessment
Risk Factors
Treatment Outcome
Venous Thromboembolism / diagnosis
Venous Thromboembolism / etiology
Venous Thromboembolism / prevention & control*

Substances

Anticoagulants
Antineoplastic Agents
Enoxaparin
Cisplatin
Aspirin